Real World Evidence, or RWE, is clinical evidence derived from data collected outside the controlled environment of a traditional clinical trial. It reflects how a device or treatment actually performs in everyday clinical practice, across the full range of patients, settings and conditions it is likely to encounter in the real world.
As regulatory frameworks evolve and the demand for robust post-market evidence grows, RWE is playing an increasingly important role in medical device development and approval.
Where Does Real World Evidence Come From?
Real World Evidence is generated from Real World Data (RWD). This is data that has been collected as part of routine clinical care rather than as part of a formal study. Common sources include electronic health records, device registries, claims and billing data, patient reported outcomes and post-market surveillance data.
The key distinction from traditional clinical trial data is the setting. A randomised controlled trial is designed to isolate specific variables under carefully controlled conditions. Real world data captures what happens when a device is used by a broader patient population, by clinicians with varying levels of experience and in a wide range of healthcare environments.
What Role Does It Play in Clinical Studies?
Supporting regulatory submissions
Under EU MDR, sponsors are required to demonstrate ongoing clinical evidence for their devices, not just at the point of approval but throughout the device lifecycle. RWE is a recognised and increasingly valued source of this evidence. It can be used to supplement data from controlled studies, support benefit-risk assessments and demonstrate real-world performance in the intended patient population.
Post-Market Clinical Follow-up
EU MDR requires manufacturers to have a Post-Market Clinical Follow-up (PMCF) plan in place. RWE is one of the primary tools for fulfilling this requirement. Device registries, user surveys and systematic review of published real-world data can all form part of a compliant PMCF strategy.
External controls and comparators
In some cases, particularly where a traditional control arm is not feasible or ethical, RWE can be used as an external comparator. This is an area that regulators including the FDA and EMA are actively developing guidance on, and it represents a significant opportunity for device sponsors to generate meaningful clinical evidence more efficiently.
Filling gaps in clinical trial data
Controlled trials are typically conducted in a defined patient population over a fixed period. RWE can help address questions that trials are not designed to answer, such as long-term outcomes, performance in specific subgroups or use in clinical settings that were not represented in the original study population.
What Are the Limitations?
RWE is not without its challenges. Because real world data is collected outside a controlled setting, it can be subject to bias, inconsistency and gaps in data quality. For RWE to be credible and regulatorily acceptable, the data sources need to be fit for purpose, the methodology needs to be rigorous and the limitations need to be transparently acknowledged.
This is why the way you collect, manage and analyse real world data matters just as much as the data itself.
Overall
Real World Evidence is no longer a secondary consideration in clinical development. It is a core part of how medical device sponsors build and maintain the clinical evidence base required for regulatory approval and post-market compliance.
Used well, RWE can reduce the burden of traditional clinical trials, support faster regulatory submissions and provide a more complete picture of how your device performs in the real world. The key is having the right strategy and the right expertise to make the most of it.
If you want to understand how real world evidence could support your clinical development programme, contact us here.
